Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.120

+1.8%

Nov 21 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	2/26/2009 11:44:15 AM
	of 3576

Merriman Curhan Sees Attractive Entry Point for Geron (GERN) Analysts at Merriman Curhan Ford are out with a positive note on stem cell company Geron (Nasdaq: GERN) today. The firm said with the stock off 37% from its recent highs it offers and attractive entry point. The firm believes there is key support in this price range and the stock could regain strength in the next couple of weeks surrounding any stem cell ban lifting by President Obama from a headline perspective. The firm sees a number of 2009 catalysts and believe GERN shares have the potential to trade toward a range of $7-$8 (currently $5.35).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next